Scipher Medicine, a leader in precision immunology, announced the public launch of ClinicalTrialRank.com, an innovative artificial intelligence (AI) platform engineered to predict clinical trial failure with unprecedented accuracy. This cutting-edge capability is poised to transform drug development, enabling biopharmaceutical companies and investors to make more informed decisions and avoid investing billions in therapies destined to fail.
ClinicalTrialRank.com is enabled by over 10 years of intensive research and technological development by Scipher Medicine’s pioneering scientists. The platform is built upon a deep understanding of the human interactome, the most comprehensive protein-protein interaction (PPI) network biology map upon which Scipher has built complex disease models. This foundational work is backed by over 100 peer-reviewed published papers, which validate its scientific rigor.
“The development model in bio-pharma is broken as too many drugs fail in the clinic. We need to better de-risk at each stage of development. Our commercial test, PrismRA, has already proven the ability to commercially de-risk development by predicting treatment response. PrismRA is the only CMS approved treatment classifier in immunology,” said Reg Seeto, CEO of Scipher Medicine. “With ClinicalTrialRank.com, we are now impacting both pre-clinical and clinical drug development. Our proven ability to predict clinical trial failure combining network medicine, AI and proprietary data, means we enhance the overall probability of clinical development success, especially when clinical failures waste tens of billions of dollars each year. These investments could otherwise be put to better use for helping patients.”
Also Read: Ajit Singh Named CEO of Harbinger Health, CEO-Partner at Flagship
The advanced technology behind ClinicalTrialRank.com goes beyond current approaches by overlaying a sophisticated genotype model, a comprehensive phenotype model, and a nuanced treatment model onto the interactome and systematically learning from the underlying network patterns of approved drugs and patients’ response to therapy. This multi-layered approach allows the platform to generate a precise ranking of therapeutic targets based on two critical factors: their proximity and relevance to disease genetic predisposition, and their ability to revert patients’ perturbed molecular profile to a healthy state.
Scipher Medicine has already applied this powerful capability across approximately 25 diverse disease areas. Through rigorous internal analysis, Scipher has conclusively demonstrated that poorly ranked targets are terminated before launch nearly 100% of the time. Across these disease areas, this represents approximately 1000 ceased clinical trials that could have been avoided, redirecting billions of dollars to more promising targets. This robust validation underscores the platform’s exceptional predictive power.
The launch of ClinicalTrialRank.com is transformative for both biopharmaceutical companies and investors alike. It provides an essential tool to de-risk pipelines, optimize R&D portfolios, and allocate capital more effectively, ultimately preventing the waste of billions of dollars on targets that are destined to fail.
Scipher’s co-founder and network biology pioneer, Albert-Laszlo Barabasi, PhD, added, “From the beginning, Scipher’s mission has been to ensure patients receive the right drug, eliminating wasteful healthcare spending.” Laszlo continued, “ClinicalTrialRank.com extends this mission to the earliest stages of drug discovery and development, ensuring that the drugs entering the clinic have the highest probability of success. This is not just about financial efficiency; it’s about accelerating the delivery of truly effective medicines to patients in need.”
Source: Businesswire